US › Healthcare

BioAge Labs, Inc (BIOA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$11.20+3.90%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.8M
Revenue YoY
+91.0%
Net profit
$-22.3M
Profit YoY
-72.1%
EPS
$-0.52
EPS estimate
$-0.71
Net margin
-802.8%

EPS came in at -0.52 against a street estimate of -0.71 — a beat of 26.8%.

Key statistics

Market cap
$479.2M
Forward P/E
0.0
P/B
1.06
Book value
$8.54
EPS (TTM)
$-2.40
52-week high
$25.95
52-week low
$4.25
50-day MA
$20.35
200-day MA
$16.52

Analyst view

Analysts rate BioAge Labs, Inc a hold (0 buy, 3 hold, 1 sell out of 4) with an average price target of $49.50.

Shareholding

Insiders
2.44%
Institutions
85.19%

Largest institutional holders

FundStake
Cormorant Asset Management, LLC6.50%
Sofinnova Ventures5.16%
BlackRock Inc5.10%
HHG PLC4.71%
Octagon Capital Advisors LP3.93%
RA Capital Management, LLC3.71%
Vanguard Group Inc3.18%
Vanguard Capital Management, LLC3.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BioAge Labs, Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.